{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T17:44:32Z","timestamp":1793036672819,"version":"4.5.0"},"reference-count":45,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2020,11,1]],"date-time":"2020-11-01T00:00:00Z","timestamp":1604188800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,11,1]],"date-time":"2020-11-01T00:00:00Z","timestamp":1604188800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,11,1]],"date-time":"2020-11-01T00:00:00Z","timestamp":1604188800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2020,11,1]],"date-time":"2020-11-01T00:00:00Z","timestamp":1604188800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2020,11,1]],"date-time":"2020-11-01T00:00:00Z","timestamp":1604188800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2020,11,1]],"date-time":"2020-11-01T00:00:00Z","timestamp":1604188800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2020,11,1]],"date-time":"2020-11-01T00:00:00Z","timestamp":1604188800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.com.au","clinicalkey.es","gynecologiconcology-online.net","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gynecologic Oncology"],"published-print":{"date-parts":[[2020,11]]},"DOI":"10.1016\/j.ygyno.2020.08.010","type":"journal-article","created":{"date-parts":[[2020,9,9]],"date-time":"2020-09-09T08:06:10Z","timestamp":1599638770000},"page":"573-580","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":36,"title":["Stereotactic body radiation therapy for oligometastatic gynecologic malignancies: A systematic review"],"prefix":"10.1016","volume":"159","author":[{"given":"Nikhil","family":"Yegya-Raman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Connie D.","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lara","family":"Hathout","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eugenia","family":"Girda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott D.","family":"Richard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Norman G.","family":"Rosenblum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neil K.","family":"Taunk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salma K.","family":"Jabbour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.ygyno.2020.08.010_bb0005","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3322\/caac.21590","article-title":"Cancer statistics, 2020","volume":"70","author":"Siegel","year":"2020","journal-title":"CA Cancer J. Clin."},{"issue":"1","key":"10.1016\/j.ygyno.2020.08.010_bb0010","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1200\/JCO.1995.13.1.8","article-title":"Oligometastases","volume":"13","author":"Hellman","year":"1995","journal-title":"J. Clin. Oncol."},{"issue":"5","key":"10.1016\/j.ygyno.2020.08.010_bb0015","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1001\/jamaoncol.2020.0147","article-title":"Outcomes of observation vs stereotactic ablative radiation for oligometastatic prostate cancer: the ORIOLE phase 2 randomized clinical trial","volume":"6","author":"Phillips","year":"2020","journal-title":"JAMA Oncol."},{"issue":"10185","key":"10.1016\/j.ygyno.2020.08.010_bb0020","doi-asserted-by":"crossref","first-page":"2051","DOI":"10.1016\/S0140-6736(18)32487-5","article-title":"Stereotactic ablative radiotherapy versus standard of care palliative treatment in patients with oligometastatic cancers (SABR-COMET): a randomised, phase 2, open-label trial","volume":"393","author":"Palma","year":"2019","journal-title":"Lancet."},{"issue":"5","key":"10.1016\/j.ygyno.2020.08.010_bb0025","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1200\/JCO.2017.75.4853","article-title":"Surveillance or metastasis-directed therapy for oligometastatic prostate cancer recurrence: a prospective, randomized, multicenter phase II trial","volume":"36","author":"Ost","year":"2018","journal-title":"J. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.ygyno.2020.08.010_bb0030","doi-asserted-by":"crossref","DOI":"10.1001\/jamaoncol.2017.3501","article-title":"Consolidative radiotherapy for limited metastatic non-small-cell lung Cancer: a phase 2 randomized clinical trial","volume":"4","author":"Iyengar","year":"2018","journal-title":"JAMA Oncol."},{"issue":"12","key":"10.1016\/j.ygyno.2020.08.010_bb0035","doi-asserted-by":"crossref","first-page":"1672","DOI":"10.1016\/S1470-2045(16)30532-0","article-title":"Local consolidative therapy versus maintenance therapy or observation for patients with oligometastatic non-small-cell lung cancer without progression after first-line systemic therapy: a multicentre, randomised, controlled, phase 2 study","volume":"17","author":"Gomez","year":"2016","journal-title":"Lancet Oncology."},{"issue":"6","key":"10.1016\/j.ygyno.2020.08.010_bb0040","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1016\/j.clon.2017.01.009","article-title":"The role of stereotactic ablative body radiotherapy in gynaecological cancers: a systematic review","volume":"29","author":"Mendez","year":"2017","journal-title":"Clin Oncol (R Coll Radiol)."},{"issue":"1","key":"10.1016\/j.ygyno.2020.08.010_bb0045","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1186\/s13014-020-1469-8","article-title":"Survey of current practices from an international task force for gynecological stereotactic ablative radiotherapy","volume":"15","author":"Leung","year":"2020","journal-title":"Radiat. Oncol."},{"issue":"1","key":"10.1016\/j.ygyno.2020.08.010_bb0050","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1186\/s12885-019-6449-8","article-title":"Stereotactic ablative radiotherapy and systemic treatments for extracerebral oligometastases, oligorecurrence, oligopersistence and oligoprogression from lung cancer","volume":"19","author":"Kissel","year":"2019","journal-title":"BMC Cancer"},{"issue":"2","key":"10.1016\/j.ygyno.2020.08.010_bb0055","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1016\/j.ijrobp.2009.09.042","article-title":"American Society for Therapeutic Radiology and Oncology (ASTRO) and American College of Radiology (ACR) practice guideline for the performance of stereotactic body radiation therapy","volume":"76","author":"Potters","year":"2010","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"issue":"2","key":"10.1016\/j.ygyno.2020.08.010_bb0060","doi-asserted-by":"crossref","first-page":"e311","DOI":"10.1634\/theoncologist.2019-0309","article-title":"A large, multicenter, retrospective study on efficacy and safety of stereotactic body radiotherapy (SBRT) in oligometastatic ovarian cancer (MITO RT1 study): a collaboration of MITO, AIRO GYN, and MaNGO groups","volume":"25","author":"Macchia","year":"2020","journal-title":"Oncologist."},{"key":"10.1016\/j.ygyno.2020.08.010_bb0065","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1136\/ijgc-2019-001115","article-title":"Stereotactic radiotherapy in patients with oligometastatic or oligoprogressive gynecological malignancies: a multi-institutional analysis","volume":"30","author":"Onal","year":"2020","journal-title":"Int. J. Gynecol. Cancer"},{"key":"10.1016\/j.ygyno.2020.08.010_bb0070","doi-asserted-by":"crossref","first-page":"S817","DOI":"10.1016\/S0167-8140(19)31930-9","article-title":"EP-1510 phase I trial of stereotactic MR-guided online adaptive radiotherapy for ovarian oligometastases","volume":"133","author":"Henke","year":"2019","journal-title":"Radiotherapy Oncol."},{"issue":"5","key":"10.1016\/j.ygyno.2020.08.010_bb0075","doi-asserted-by":"crossref","first-page":"e175","DOI":"10.1111\/ajco.13159","article-title":"Stereotactic body radiation therapy for oligometastatic pulmonary tumors from cervical cancer","volume":"15","author":"Hou","year":"2019","journal-title":"Asia Pac J Clin Oncol."},{"issue":"1","key":"10.1016\/j.ygyno.2020.08.010_bb0080","first-page":"E569","article-title":"Clinical Outcomes of Stereotactic Body Radiation Therapy for Extracranial Oligometastatic Ovarian Cancer","volume":"105","author":"Mills","year":"2019","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"issue":"1","key":"10.1016\/j.ygyno.2020.08.010_bb0085","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.ygyno.2017.10.017","article-title":"Outcomes and patterns of relapse after definitive radiation therapy for oligometastatic cervical cancer","volume":"148","author":"Ning","year":"2018","journal-title":"Gynecol. Oncol."},{"issue":"2","key":"10.1016\/j.ygyno.2020.08.010_bb0090","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1097\/IGC.0000000000000885","article-title":"Clinical outcomes of stereotactic body radiotherapy in oligometastatic gynecological cancer","volume":"27","author":"Laliscia","year":"2017","journal-title":"Int. J. Gynecol. Cancer"},{"issue":"2","key":"10.1016\/j.ygyno.2020.08.010_bb0095","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1097\/IGC.0000000000000869","article-title":"Clinical outcomes for stereotactic ablative radiotherapy in oligometastatic and oligoprogressive gynecological malignancies","volume":"27","author":"Mesko","year":"2017","journal-title":"Int. J. Gynecol. Cancer"},{"key":"10.1016\/j.ygyno.2020.08.010_bb0100","doi-asserted-by":"crossref","first-page":"126","DOI":"10.3389\/fonc.2015.00126","article-title":"Phase I trial of carboplatin and gemcitabine chemotherapy and stereotactic ablative radiosurgery for the palliative treatment of persistent or recurrent gynecologic cancer","volume":"5","author":"Kunos","year":"2015","journal-title":"Front. Oncol."},{"issue":"9","key":"10.1016\/j.ygyno.2020.08.010_bb0105","first-page":"5103","article-title":"Stereotactic body radiotherapy for recurrent or oligometastatic uterine cervix cancer: a cooperative study of the Korean radiation oncology group (KROG 14-11)","volume":"35","author":"Park","year":"2015","journal-title":"Anticancer Res."},{"issue":"5","key":"10.1016\/j.ygyno.2020.08.010_bb0110","doi-asserted-by":"crossref","first-page":"180","DOI":"10.3109\/07357907.2015.1019678","article-title":"Stereotactic body radiotherapy for oligometastases confined to the para-aortic region: clinical outcomes and the significance of radiotherapy field and dose","volume":"33","author":"Seo","year":"2015","journal-title":"Cancer Investig."},{"issue":"1","key":"10.1016\/j.ygyno.2020.08.010_bb0115","doi-asserted-by":"crossref","first-page":"S908","DOI":"10.1016\/j.ijrobp.2014.05.2579","article-title":"Stereotactic ablative radiation therapy for gynecological malignancies in the oligometastatic setting","volume":"90","author":"Broomfield","year":"2014","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"issue":"5","key":"10.1016\/j.ygyno.2020.08.010_bb0120","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1177\/030089161309900509","article-title":"Clinical outcome of stereotactic body radiotherapy for abdominal lymph node metastases","volume":"99","author":"Bonomo","year":"2013","journal-title":"Tumori."},{"issue":"3","key":"10.1016\/j.ygyno.2020.08.010_bb0125","doi-asserted-by":"crossref","first-page":"S448","DOI":"10.1016\/j.ijrobp.2012.07.1187","article-title":"Stereotactic Body Radiation Therapy (SBRT) for Single Small (<5 cm) Extracranial Ovarian or Uterine Cancer Metastases: Promising Local Control and Normal Tissue Tolerance With 5 Fraction Approach","volume":"84","author":"Chaudhry","year":"2012","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"10.1016\/j.ygyno.2020.08.010_bb0130","doi-asserted-by":"crossref","first-page":"181","DOI":"10.3389\/fonc.2012.00181","article-title":"Phase II clinical trial of robotic stereotactic body radiosurgery for metastatic gynecologic malignancies","volume":"2","author":"Kunos","year":"2012","journal-title":"Front. Oncol."},{"issue":"3","key":"10.1016\/j.ygyno.2020.08.010_bb0135","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1016\/j.ygyno.2010.11.042","article-title":"Stereotactic body radiotherapy (SBRT): technological innovation and application in gynecologic oncology","volume":"120","author":"Higginson","year":"2011","journal-title":"Gynecol. Oncol."},{"issue":"1","key":"10.1016\/j.ygyno.2020.08.010_bb0140","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/j.ijrobp.2008.07.020","article-title":"Image-guided stereotactic body radiation therapy in patients with isolated para-aortic lymph node metastases from uterine cervical and corpus cancer","volume":"74","author":"Choi","year":"2009","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"issue":"2","key":"10.1016\/j.ygyno.2020.08.010_bb0145","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1093\/annonc\/mdt537","article-title":"Stereotactic radiotherapy for oligometastatic cancer: a prognostic model for survival","volume":"25","author":"de Vin","year":"2014","journal-title":"Ann. Oncol."},{"issue":"2","key":"10.1016\/j.ygyno.2020.08.010_bb0150","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.radonc.2014.12.003","article-title":"Survival and prognostic factors in 321 patients treated with stereotactic body radiotherapy for oligo-metastases","volume":"114","author":"Fode","year":"2015","journal-title":"Radiotherapy Oncol."},{"issue":"14","key":"10.1016\/j.ygyno.2020.08.010_bb0155","doi-asserted-by":"crossref","first-page":"2242","DOI":"10.1002\/cncr.30058","article-title":"Clinical and molecular markers of long-term survival after oligometastasis-directed stereotactic body radiotherapy (SBRT)","volume":"122","author":"Wong","year":"2016","journal-title":"Cancer."},{"issue":"4","key":"10.1016\/j.ygyno.2020.08.010_bb0160","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0195149","article-title":"Classification for long-term survival in oligometastatic patients treated with ablative radiotherapy: a multi-institutional pooled analysis","volume":"13","author":"Hong","year":"2018","journal-title":"PLoS One"},{"issue":"1","key":"10.1016\/j.ygyno.2020.08.010_bb0165","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.ijrobp.2018.12.049","article-title":"Predictive factors for response and survival in a cohort of oligometastatic patients treated with stereotactic body radiation therapy","volume":"104","author":"Franceschini","year":"2019","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"issue":"1094","key":"10.1016\/j.ygyno.2020.08.010_bb0170","doi-asserted-by":"crossref","first-page":"20180422","DOI":"10.1259\/bjr.20180422","article-title":"Dose escalation in extracranial stereotactic ablative radiotherapy (DESTROY-1): a multiarm phase I trial","volume":"92","author":"Deodato","year":"2019","journal-title":"Br. J. Radiol."},{"issue":"7","key":"10.1016\/j.ygyno.2020.08.010_bb0175","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1007\/s11864-020-00748-6","article-title":"Stereotactic ablative radiotherapy for recurrent or metastatic gynecological cancer: extending lives?","volume":"21","author":"Zhang","year":"2020","journal-title":"Curr. Treat. Options in Oncol."},{"issue":"12","key":"10.1016\/j.ygyno.2020.08.010_bb0180","doi-asserted-by":"crossref","first-page":"2109","DOI":"10.1016\/j.jtho.2019.07.025","article-title":"Definition of synchronous oligometastatic non-small cell lung cancer-a consensus report","volume":"14","author":"Dingemans","year":"2019","journal-title":"J. Thorac. Oncol."},{"issue":"1","key":"10.1016\/j.ygyno.2020.08.010_bb0185","doi-asserted-by":"crossref","first-page":"e18","DOI":"10.1016\/S1470-2045(19)30718-1","article-title":"Characterisation and classification of oligometastatic disease: a European Society for Radiotherapy and Oncology and European organisation for research and treatment of cancer consensus recommendation","volume":"21","author":"Guckenberger","year":"2020","journal-title":"The Lancet Oncology."},{"issue":"1","key":"10.1016\/j.ygyno.2020.08.010_bb0190","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1016\/j.ygyno.2019.03.255","article-title":"Immunotherapy and radiation combinatorial trials in gynecologic cancer: a potential synergy?","volume":"154","author":"Lee","year":"2019","journal-title":"Gynecol. Oncol."},{"issue":"7","key":"10.1016\/j.ygyno.2020.08.010_bb0195","doi-asserted-by":"crossref","first-page":"2488","DOI":"10.1158\/0008-5472.CAN-10-2820","article-title":"The efficacy of radiotherapy relies upon induction of type i interferon-dependent innate and adaptive immunity","volume":"71","author":"Burnette","year":"2011","journal-title":"Cancer Res."},{"issue":"12","key":"10.1016\/j.ygyno.2020.08.010_bb0200","doi-asserted-by":"crossref","first-page":"1845","DOI":"10.1038\/s41591-018-0232-2","article-title":"Radiotherapy induces responses of lung cancer to CTLA-4 blockade","volume":"24","author":"Formenti","year":"2018","journal-title":"Nat. Med."},{"issue":"4","key":"10.1016\/j.ygyno.2020.08.010_bb0205","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1136\/ijgc-2020-001227","article-title":"Combining novel agents with radiotherapy for gynecologic malignancies: beyond the era of cisplatin","volume":"30","author":"Lin","year":"2020","journal-title":"Int. J. Gynecol. Cancer"},{"issue":"16","key":"10.1016\/j.ygyno.2020.08.010_bb0210","doi-asserted-by":"crossref","first-page":"1814","DOI":"10.1200\/JCO.19.02059","article-title":"Randomized phase II trial of nivolumab versus nivolumab and ipilimumab for recurrent or persistent ovarian cancer: an NRG oncology study","volume":"38","author":"Zamarin","year":"2020","journal-title":"J. Clin. Oncol."},{"issue":"17","key":"10.1016\/j.ygyno.2020.08.010_bb0215","doi-asserted-by":"crossref","first-page":"1470","DOI":"10.1200\/JCO.18.01265","article-title":"Efficacy and safety of pembrolizumab in previously treated advanced cervical cancer: results from the phase II KEYNOTE-158 study","volume":"37","author":"Chung","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2020.08.010_bb0220","doi-asserted-by":"crossref","first-page":"v898","DOI":"10.1093\/annonc\/mdz394.059","article-title":"LBA62 - efficacy and safety of nivolumab (nivo) + ipilimumab (ipi) in patients (pts) with recurrent\/metastatic (R\/M) cervical cancer: results from CheckMate 358","volume":"30","author":"Naumann","year":"2019","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.ygyno.2020.08.010_bb0225","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.19.02627","article-title":"Lenvatinib Plus Pembrolizumab in Patients With Advanced Endometrial Cancer","author":"Makker","year":"2020","journal-title":"J Clin Oncol"}],"container-title":["Gynecologic Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825820338087?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825820338087?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,5,16]],"date-time":"2024-05-16T08:03:51Z","timestamp":1715846631000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090825820338087"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11]]},"references-count":45,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2020,11]]}},"alternative-id":["S0090825820338087"],"URL":"https:\/\/doi.org\/10.1016\/j.ygyno.2020.08.010","relation":{},"ISSN":["0090-8258"],"issn-type":[{"value":"0090-8258","type":"print"}],"subject":[],"published":{"date-parts":[[2020,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Stereotactic body radiation therapy for oligometastatic gynecologic malignancies: A systematic review","name":"articletitle","label":"Article Title"},{"value":"Gynecologic Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ygyno.2020.08.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}